Immunovant flashes the data that made Roivant want to reacquire it at a potentially hefty premium

The “non-public information” that made Roivant want to acquire their troubled spinout at a potentially substantial premium just became public.

Immunovant, the autoimmune-focused vant, announced Tuesday that they saw a path forward for bringing their lead and only drug back into development, after safety issues forced the company to pause its only two active trials over the winter. They now plan to launch a pivotal trial for the rare disease myasthenia gravis by early 2022, while adding three mid-stage studies for other autoimmune disorders.